340B Compliance Runs on Documentation
In a 340B program, the disposal record is part of the audit trail. Recovering credit on returnable product protects the program's economics, but the bigger risk is a return or destruction you cannot fully document when auditors ask. Every unit that leaves inventory, whether for credit or for destruction, needs a defensible paper trail tied to the right waste stream. What sets a 340B pharmacy apart is not a separate disposal law but the expectation that disposal reconciles against inventory the same way dispensing does. A carton of expired stock thrown out without a record is not just lost credit; it is a gap a program integrity audit can flag. The pharmacies that stay clean treat every unit removed from the shelf, for any reason, as a documented event rather than housekeeping.
The Frameworks Behind a 340B Pharmacy
Your controlled-substance wastage answers to DEA 21 CFR 1317. Form 222 governs Schedule II transfers where they apply, and Form 41 evidences non-retrievable destruction of surrendered controls. RCRA-hazardous drugs, including the P- and U-listed categories, sit under EPA 40 CFR, with Subpart P (40 CFR 266) tailored to hazardous pharmaceutical waste and dependent on your generator status. Non-controlled, non-hazardous Rx is pharmaceutical waste that must be destroyed with documentation, never drain-disposed. Sharps from immunization and point-of-care services fall under OSHA's Bloodborne Pathogens Standard, 29 CFR 1910.1030. Each framework carries its own record, and in a 340B setting those records do double duty, satisfying DEA, state board, and EPA rules while also feeding the accountability file a HRSA-oriented audit expects to see.
Reverse Distribution Protects the Margin
Reverse distribution is where 340B economics and compliance meet. Expired, overstocked, discontinued, and recalled returnable product, brand and generic, moves through a reverse distributor that processes eligible units for manufacturer credit and destroys the rest with documentation. The costly mistake is pre-sorting product into the trash: items a pharmacy assumes are worthless are often still credit-eligible, and once they are commingled with waste that credit is gone. Opened or adulterated product and patient-owned medications are destroy-only and should never enter the returns stream. For a program already operating on thin margins, disciplined reverse distribution recovers dollars that would otherwise be discarded, and it produces the documented return records that make the program defensible when a payer or manufacturer questions a claim.